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Introduction
Typical and atypical antipsychotic drugs are effective treatments for schizophrenia. However, despite best attempts to optimize therapy, fewer than 15% of treated patients recover. 1 Most patients continue to exhibit a mix of positive, negative, and cognitive symptoms, and some are considerably impaired by these. Raising (or lowering) the antipsychotic dose, switching antipsychotics, and augmenting with a second antipsychotic are examples of pharmacologic interventions that are antipsychotic-based. For patients in whom antipsychotic approaches fail, and for those who do not tolerate antipsychotic drugs well, are there augmentation approaches involving non-antipsychotic drugs? A previous article in this column suggested that famotidine augmentation may not be of much benefit. 2 The present article examines 2 other innovative augmentation treatments: nonsteroidal anti-inflammatory drugs (NSAIDs) and 5-HT 3 serotonin receptor antagonists.
Mechanisms
Inflammatory markers have been identified in plasma as well as brain before and during the onset of psychotic symptoms in schizophrenia [3] [4] [5] ; if these contribute to the disease process, then anti-inflammatory treatments may attenuate the severity of schizophrenia. 6 5-HT 3 receptors are widely distributed in the brain, including in limbic and frontal cortical areas. These receptors result in downstream modulation of many neurotransmitters, including dopamine. These receptors also influence auditory gating in schizophrenia. 7 5-HT 3 receptors probably do not modulate basal dopamine release but facilitate reward-related phasic dopamine release in the nucleus accumbens. 5-HT 3 antagonists reduce dopaminergic activity in the nucleus accumbens. 8 5-HT 3 antagonists have been used to treat different dopaminergic disorders such as tardive dyskinesia, 9 Tourette's disorder, 10 and schizophrenia. 11 Finally, 5-HT 3 antagonists have a calming effect and improve cognition in animal models. 12, 13 Drugs acting on 5-HT 3 receptors may therefore moderate the symptoms of schizophrenia.
NSAIDs for Schizophrenia
Many randomized controlled trials (RCTs) have examined whether NSAID augmentation is an effective treatment strategy in schizophrenia; not all outcomes were favorable. Nitta et al 14 therefore examined the subject in a systematic review and metaanalysis. The authors searched electronic databases, clinical trial registries, reference lists, and other sources and identified 8 relevant placebo-controlled RCTs (pooled N = 774), including 3 that had not been published. These RCTs examined acutely ill schizophrenia patients and those with positive symptoms. The mean age of the pooled sample was about 34 years. The sample was two-thirds male. Risperidone was the commonest antipsychotic that was augmented. Six RCTs examined celecoxib (400 mg/d; N = 504) and 2 examined aspirin (1,000 mg/d; N = 270) augmentation. The trials were 5 to 16 (median = 8) weeks in duration.
Nitta et al 14 found that NSAID augmentation of antipsychotic drugs was associated with a statistically significant reduction in positive symptoms scores; however, the standardized mean difference (SMD) was only 0.19, representing an effect size of questionable clinical significance. The SMD for Positive and Negative Syndrome Scale (PANSS) total scores narrowly missed statistical significance; this effect was also small and likely to be of doubtful clinical value. There were no other treatment gains evident. Dropout was not increased by NSAID augmentation.
Many subgroup analyses suggested possible areas of benefit, but these results are best considered preliminary because the analyses were exploratory and not corrected for type II errors. The results of the meta-analysis are summarized in Table 1 . In brief, the findings do not encourage the use of anti-inflammatory treatments for schizophrenia unless inflammatory or other biomarkers can be identified that reliably define subpopulations of patients who might benefit from the intervention. In such an event, long-term studies are desirable to determine whether reducing inflammation improves the course of the illness.
5-HT 3 Antagonists for Schizophrenia
Kishi et al 11 presented a systematic review and metaanalysis of selective 5-HT 3 antagonist augmentation of antipsychotic medications in schizophrenia. These authors searched electronic databases, clinical trial registries, reference lists, and other sources and identified 6 relevant placebo-controlled RCTs (pooled N = 311), only 5 of which contributed data to efficacy outcomes. The mean age of the sample was about 37 years. Patients in these studies were, in general, clinically stable and on stable doses of antipsychotic medication. The RCTs ranged from 10 days to 12 weeks (median, 8 weeks) in duration. Three RCTs studied tropisetron (5-10 mg/d), 2 studied ondansetron (8 mg/d),
Clinical Points
Some schizophrenia patients may require antipsychotic ■ augmentation treatments to manage residual positive, negative, or other symptoms. In this regard, nonsteroidal anti-inflammatory drugs (NSAIDs) and 5-HT 3 antagonists are 2 novel augmentation strategies that have been studied and meta-analyzed.
The results with NSAIDs in patients with acute illness and ■ those with persistent positive symptoms have been mostly disappointing; only improvements in positive symptoms have been found, and the pooled effect size is probably too small to be clinically relevant.
The results with 5-HT ■ 3 antagonists in stable patients are more promising; negative symptoms, general psychopathology, and total symptom ratings have all been shown to attenuate. However, the literature in the field is insufficient for definitive recommendations to be made. 12; 95% CI, −0.12 to 0.36). 5. Constipation was more common with 5-HT 3 antagonists (risk ratio = 2.05; 95% CI, 1.07-3.91; NNH = 11). 6. In one study, extrapyramidal symptom ratings were significantly lower with ondansetron, and in another study, nausea and vomiting were significantly lower with ondansetron. 7. Dropout due to inefficacy, adverse events, and all causes was similar in treatment and control groups.
Abbreviations: NNH = number needed to harm, PANSS = Positive and Negative Syndrome Scale, RCT = randomized controlled trial, SMD = standardized mean difference. The results of the meta-analysis are summarized in Table 2 . 5-HT 3 antagonists were associated with significant reductions in PANSS total scores, negative symptoms, and general psychopathology scores; the SMDs were medium to large. All 3 analyses, however, were characterized by statistical heterogeneity. 5-HT 3 antagonists did not significantly reduce positive symptoms. Dropout rates were not increased by 5-HT 3 antagonists.
These results should, at best, be considered preliminary because of the small number of studies, the small size of the pooled sample, and the considerable heterogeneity detected in the analyses. However, the large effect sizes across several outcome measures imply that the field is worthy of further study.
Conclusions
Nonsteroidal anti-inflammatory drugs seem to hold little promise as antipsychotic augmentation agents in acutely ill schizophrenia patients or those with persistent positive symptoms. However, these drugs may merit investigation in samples of patients in whom biomarkers of neuroinflammatory pathology suggest the possibility of benefit. 5-HT 3 antagonists may improve negative symptoms, general psychopathology, and overall symptom ratings in schizophrenia patients who are on a stable dose of antipsychotic medication; the field, however, requires stronger evidence before definitive conclusions can be drawn.
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Where does this leave the 2 patients who were described at the start of this article? At best, a 5-HT 3 antagonist may be trialed in each patient as an experimental, off-label augmenting agent for a period of about 8 weeks. The data suggest that, whereas there can be hopes of improvement, the risks (except for constipation) are no greater than with placebo.
